rad.base.eth 💢(💙,🧡)☉ ℝ∀🍚⛓.ink | 𝔽rAI π²🌶️
5.1K posts

rad.base.eth 💢(💙,🧡)☉ ℝ∀🍚⛓.ink | 𝔽rAI π²🌶️
@HradmanAli
| Fuelet @0mniScore Fam 👾 #byebyebirdie💙 https://t.co/iGBwDRpi69 Army https://t.co/bsclaRJQc0 $StarkDefi 🏰https://t.co/HwVfYKFz8t #STEER @tapioca_dao🛡️ 🌘 $FAN Maxi VBDR2GPH








🩺 Community Question: In medical innovation, what drives greater long-term impact: U.S.-grade quality for rigorous validation and strict regulation or Asia-speed execution for faster approvals and rapid scale? Viewpoint A: U.S.-Grade Quality Through institutions like the U.S. Food and Drug Administration, the U.S. emphasizes deep clinical validation before approval. Rigor reduces risk, protects trust, and supports durable breakthrough innovation. Viewpoint B: Asia-Speed Execution Countries such as China and India accelerate approvals and deploy innovations at scale. Faster access can save lives, especially in high-burden diseases. 👇 Drop A or B and share your perspective.









Announcing: Linera Markets. Waitlist opens tomorrow.


